Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094632 | 0.95 | TSHR (0.52) | TSHRALDH1A1HPGDCNR2FFAR1 | |
| SCHEMBL12255638 | 0.91 | TSHR (0.56) | TSHRALDH1A1HPGDCNR2FFAR1 | |
| SCHEMBL15266535 | 0.83 | TSHR (0.49) | TSHRALDH1A1HPGDCNR2FFAR1 | |
| SCHEMBL1558841 | 0.81 | ALDH1A1 (0.51) | TSHRALDH1A1HPGDFFAR1GAA | |
| SCHEMBL29045424 | 0.81 | FFAR1 (0.46) | TSHRALDH1A1FFAR1GAAMAPT | |
| SCHEMBL7906876 | 0.81 | FFAR1 (0.56) | ALDH1A1FFAR1MAPT | |
| SCHEMBL18801996 | 0.79 | CYP4F2 (0.54) | TSHRALDH1A1HPGDMAPTCYP4F2 | |
| SCHEMBL7254900 | 0.78 | MAPT (0.46) | TSHRALDH1A1HPGDFFAR1GAA | |
| SCHEMBL6002358 | 0.78 | TSHR (0.44) | TSHRALDH1A1HPGDCNR2FFAR1 | |
| SCHEMBL8935206 | 0.78 | CYP4F2 (0.49) | TSHRALDH1A1HPGDMAPTCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TSHR 681/4885ALDH1A1 1819/4885HPGD 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.